Document is current
Any future updates will be listed below
-
Authors
Kim, Soon-Chan
Kim, Ga-Hye
Park, Jae-Hyeon
Lee, Kyung-Hun
Koh, Jiwon
Kim, Tae-Yong
Lee, Dae-Won
Kim, Yu-Jin
Kim, Seongyeong
Park, Song-Yi
Min, Ahrum
Shin, Young-Kyoung
Im, Seock-Ah
Ku, Ja-Lok
-
Funding
Funding for this research was provided by:
National Research Foundation of Korea (2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217)
National Research Foundation of Korea (2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217)
National Research Foundation of Korea (2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217)
National Research Foundation of Korea (2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217)
National Research Foundation of Korea (2021M3H9A1030151, NRF2022R1A5A102641311, 2022M3A9B6018217)
Korean Cell Line Research Foundation
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111)
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111)
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111)
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111)
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111)
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111)
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111)
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111)
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0111)
- License Information
-
More Information
Article History
Received: 18 November 2024
Accepted: 22 April 2025
First Online: 1 May 2025
Declarations
:
: The research protocol was reviewed and approved by the institutional review board of the Seoul National University Hospital (IRB No. 1102–098-357). The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients enrolled in this study.
: Not applicable.
: Seock-Ah Im received research fund from AstraZeneca, Boryung, Eisai, and Pfizer outside of this research work. Seock-Ah Im has advisory role for AstraZeneca, Eisai, Eli-Lilly, MSD, Novartis, Roche, Pfizer outside of this research work.
